Trial Profile
A Phase II Study of Picoplatin as Second-Line Therapy for Subjects With Resistant or Refractory Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2009
Price :
$35
*
At a glance
- Drugs Picoplatin (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 20 Apr 2009 Results published in the Journal of Clinical Oncology.
- 23 Apr 2008 Final results reported at ASLO and ESMO 2008, according to a Poniard Pharmaceutical media release.
- 23 Apr 2008 Status change from in progress to completed, according to a Poniard Pharmaceuticals media release.